The purpose of the study is to determine adverse events rates of nebulized albuterol versus levalbuterol among adult critically ill patients and determine if a differential exists in adverse events between the two drugs.
A randomized, single-blind, cross-over, prospective study was conducted in seventy critically ill adult patients with acute air flow obstruction. Patients were randomized to nebulized albuterol alternating with levalbuterol every 4 to 6 hours. Group A received albuterol 2.5 mg alternating with levalbuterol 0.63 mg. Group B received albuterol 2.5 mg alternating with levalbuterol 1.25 mg. All patients received nebulized ipratropium bromide 500 micrograms with each treatment. Heart rate and cardiac rhythm were continuously recorded before and 15 minutes after finishing each treatment. Any new rhythm abnormalities between treatments were also recorded.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Enrollment
89
inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
Nebulized albuterol 2.5mg
Genesys Regional Medical Center
Grand Blanc, Michigan, United States
Heart Rate in Beats Per Minute
Average difference in Heart rate between pre and post breathing treatments
Time frame: Five days
Arrhythmias
Any new arrhythmia documented in the medical record that occurred between breathing treatments.
Time frame: 15 minutes after each treatment for average of 3 to 5 days
Total Number of Participants With Arrhythmias
Documented new arrhythmia occurring during study.
Time frame: Five days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.